Activity of blinatumomab in patients with relapsed/refractory ALL
| Parameter . | N (%) . | |
|---|---|---|
| Pivotal study, n = 36 . | Confirmatory study, n = 189 . | |
| Response | ||
| CR | 15 (42) | 62 (33) |
| CR with incomplete count recovery | 10 (28) | 19 (10) |
| All responders | 25 (69) | 81 (43) |
| Salvage status | ||
| Salvage 1 | 11 (31) | 38 (20) |
| Salvage 2+ | 10 (28) | 151 (80) |
| Median survival (months) | 9.8 | 6.1 |
| Parameter . | N (%) . | |
|---|---|---|
| Pivotal study, n = 36 . | Confirmatory study, n = 189 . | |
| Response | ||
| CR | 15 (42) | 62 (33) |
| CR with incomplete count recovery | 10 (28) | 19 (10) |
| All responders | 25 (69) | 81 (43) |
| Salvage status | ||
| Salvage 1 | 11 (31) | 38 (20) |
| Salvage 2+ | 10 (28) | 151 (80) |
| Median survival (months) | 9.8 | 6.1 |